JPH09500092A - B群れんさ球菌の多くの菌株に対する免疫を与える細胞表面タンパク質であるタンパク質Rib、そのタンパク質の精製方法、薬剤キットおよび医薬組成物 - Google Patents
B群れんさ球菌の多くの菌株に対する免疫を与える細胞表面タンパク質であるタンパク質Rib、そのタンパク質の精製方法、薬剤キットおよび医薬組成物Info
- Publication number
- JPH09500092A JPH09500092A JP6520946A JP52094694A JPH09500092A JP H09500092 A JPH09500092 A JP H09500092A JP 6520946 A JP6520946 A JP 6520946A JP 52094694 A JP52094694 A JP 52094694A JP H09500092 A JPH09500092 A JP H09500092A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- rib
- strains
- strain
- streptococcus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 197
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 194
- 241000193990 Streptococcus sp. 'group B' Species 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000036039 immunity Effects 0.000 title claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 102000018697 Membrane Proteins Human genes 0.000 title description 6
- 108010052285 Membrane Proteins Proteins 0.000 title description 6
- 239000003814 drug Substances 0.000 claims abstract description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 230000001681 protective effect Effects 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims description 24
- 238000002523 gelfiltration Methods 0.000 claims description 11
- 108010009719 mutanolysin Proteins 0.000 claims description 11
- 108090000631 Trypsin Proteins 0.000 claims description 10
- 102000004142 Trypsin Human genes 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000012588 trypsin Substances 0.000 claims description 10
- 102000057297 Pepsin A Human genes 0.000 claims description 9
- 108090000284 Pepsin A Proteins 0.000 claims description 9
- 229940111202 pepsin Drugs 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 7
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 6
- 238000004255 ion exchange chromatography Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 24
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 22
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- 239000000284 extract Substances 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000007983 Tris buffer Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 13
- 239000012528 membrane Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 239000004365 Protease Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 208000020241 Neonatal disease Diseases 0.000 description 5
- 208000037129 Newborn Diseases Infant Diseases 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 5
- 101710120037 Toxin CcdB Proteins 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 231100000518 lethal Toxicity 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- MXVMRHIWTSFDPU-UHFFFAOYSA-N 2-chlorobenzenecarboximidamide Chemical compound NC(=N)C1=CC=CC=C1Cl MXVMRHIWTSFDPU-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920009537 polybutylene succinate adipate Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150056293 AJUBA gene Proteins 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000682622 Andracantha sigma Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000002714 Extracts of rosemary Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RERHJVNYJKZHLJ-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;2-(3,5-diiodo-4-oxopyridin-1-yl)acetate Chemical compound OCCNCCO.OC(=O)CN1C=C(I)C(=O)C(I)=C1 RERHJVNYJKZHLJ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- CIJQGPVMMRXSQW-UHFFFAOYSA-M sodium;2-aminoacetic acid;hydroxide Chemical compound O.[Na+].NCC([O-])=O CIJQGPVMMRXSQW-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.Rib と呼称される精製タンパク質であって; (a) B群れんさ球菌菌株、特に血清型IIIの該菌株から得ることができ; (b) トリプシンおよびペプシンによる分解に対して比較的耐性であり; (c) 配列番号:1のN末端アミノ酸配列またはこの配列に対し少なくとも90% の相同性の配列を有し;および (d) 該タンパク質を発現するB群れんさ球菌菌株に対する防御免疫を与える; ことを特徴とするタンパク質;ならびに防御免疫を与える性能を有する、該タン パク質の天然産または人工的に修飾された変異体、サブフラグメントおよび多重 体。 2.前記菌株が菌株BS30またはBM110であり、前記タンパク質がSDS − P AGE で測定した場合、約95KDの見掛けの分子量を有する請求の範囲1記載のタ ンパク質。 3.タンパク質Rib を発現するB群れんさ球菌菌株を培養し、その培地および /または微生物を単離し、その細菌を酵素好ましくはムタノリシンで消化し、任 意にプロテアーゼインヒビターを添加し、消化した細菌を上澄み液から分離し、 次いでタンパク質Rib を上澄み液から抽出することを特徴とするタンパク質Rib の単離方法。 4.前記タンパク質を、透析、イオン交換クロマトグラフィーによる分画、お よびゲル濾過によって、前記上澄み液から抽出する請求の範囲3記載の方法。 5.請求の範囲1に定義されているタンパク質Rib なら びにその変異体、サブフラグメントおよび多重体に対して高度に特異的な抗体。 6.請求の範囲1に定義されているタンパク質Rib またはその変異体、サブフ ラグメントおよび多重体が入っていることを特徴とする、タンパク質Rib に対す る抗体を検出するのに用いる薬剤キット。 7.請求の範囲1に定義されているタンパク質に特異的な抗体が入っており、 そして任意に、タンパク質Rib ならびにその変異体、サブフラグメントおよび/ または多重体が標準として入っていることを特徴とする、タンパク質Rib を検出 するのに用いる薬剤キット。 8.請求の範囲1に定義されているタンパク質Rib またはその変異体、サブフ ラグメントもしくは多重体をコードするDNA 配列を含有しているベクター。 9.タンパク質Rib をコードするベクターのDNA 配列が、寄託番号がDSM...で あるファージλRib 1−3の対応する配列のいずれかと事実上同じであることを 特徴とする請求の範囲8記載のベクター。 10.タンパク質Rib をコードするベクターのDNA 配列が、寄託番号がDSM...で あるファージλRib 1−5の対応するDNA 配列のいずれかと事実上同一であるこ とを特徴とする請求の範囲8記載のベクター。 11.タンパク質Rib をコードするベクターのDNA 配列が、寄託番号がDSM...で あるファージλRib 1−7の対応するDNA 配列のいずれかと事実上同じであるこ とを特徴とする請求の範囲8記載のベクター。 12.寄託番号がDSM...であるファージλRib 1−3。 13.寄託番号がDSM...であるファージλRib 1−5。 14.寄託番号がDSM...であるファージλRib 1−7。 15.請求の範囲8に定義されているベクターから得ることができる、タンパク 質Rib またはその変異体、サブフラグメントもしくは多重体をコードするDNA 配 列。 16.請求の範囲1に定義されているタンパク質Rib またはその変異体、サブフ ラグメントもしくは多重体を含有し、さらに医薬として許容される佐剤または賦 形剤を含有する医薬組成物。 17.請求の範囲1に定義されているタンパク質Rib またはその変異体、サブフ ラグメントもしくは多重体を含有し、さらに医薬として許容される佐剤または賦 形剤を含有するワクチン。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
WO93/00234 | 1993-03-19 | ||
SE9300234 | 1993-03-19 | ||
PCT/SE1994/000246 WO1994021685A1 (en) | 1993-03-19 | 1994-03-21 | Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09500092A true JPH09500092A (ja) | 1997-01-07 |
JP3976334B2 JP3976334B2 (ja) | 2007-09-19 |
Family
ID=20388669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52094694A Expired - Fee Related JP3976334B2 (ja) | 1993-03-19 | 1994-03-21 | B群れんさ球菌の多くの菌株に対する免疫を与える細胞表面タンパク質であるタンパク質Rib、そのタンパク質の精製方法、薬剤キットおよび医薬組成物 |
Country Status (18)
Country | Link |
---|---|
US (1) | US5869064A (ja) |
EP (1) | EP0656014B1 (ja) |
JP (1) | JP3976334B2 (ja) |
KR (1) | KR100331358B1 (ja) |
CN (1) | CN1046291C (ja) |
AT (1) | ATE240351T1 (ja) |
CA (1) | CA2158658A1 (ja) |
DE (1) | DE69432658T2 (ja) |
DK (1) | DK0656014T3 (ja) |
ES (1) | ES2194024T3 (ja) |
HK (1) | HK1008825A1 (ja) |
HU (1) | HU217582B (ja) |
NZ (1) | NZ263275A (ja) |
PT (1) | PT656014E (ja) |
SG (1) | SG47049A1 (ja) |
SI (1) | SI0656014T1 (ja) |
WO (1) | WO1994021685A1 (ja) |
ZA (1) | ZA941958B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002533083A (ja) * | 1998-12-22 | 2002-10-08 | マイクロサイエンス リミテッド | 遺伝子およびたんぱく質、およびそれらの用途 |
JP2002533065A (ja) * | 1998-12-22 | 2002-10-08 | マイクロサイエンス リミテッド | 外表面たんぱく質、それらの遺伝子、およびそれらの用途 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015889A (en) | 1993-03-19 | 2000-01-18 | Gunnar Lindahl | Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition |
CA2321106C (en) | 1998-02-20 | 2013-07-23 | Biochem Pharma Inc. | Group b streptococcus antigens |
US6890539B2 (en) | 1998-12-22 | 2005-05-10 | Microscience, Ltd. | Genes and proteins, and their use |
NZ512574A (en) * | 1998-12-23 | 2004-03-26 | Iaf Biochem Int | Novel streptococcus antigens useful as vaccines |
US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
GB9910375D0 (en) | 1999-05-05 | 1999-06-30 | Lindahl Gunnar | Vaccine composition |
CA2447750C (en) * | 2001-05-31 | 2012-12-18 | Fuso Pharmaceutical Industries, Ltd. | Improved method for detecting and identifying causative microorganisms of infectious diseases |
JPWO2002101037A1 (ja) * | 2001-05-31 | 2005-04-07 | 扶桑薬品工業株式会社 | 食細胞機能の評価方法およびその利用 |
WO2003068813A2 (en) * | 2002-02-11 | 2003-08-21 | Shire Biochem Inc | Group b streptococcus antigen |
US20070014841A1 (en) * | 2005-02-08 | 2007-01-18 | Denis Martin | Pharmaceutical compositions |
EP2144924B1 (en) | 2007-04-16 | 2016-05-11 | MinervaX Aps | Fusion protein vaccine |
CN108135992A (zh) | 2015-10-21 | 2018-06-08 | 米纳瓦克斯有限责任公司 | 免疫原性融合蛋白 |
WO2017114655A1 (en) | 2015-12-30 | 2017-07-06 | Minervax Aps | Immunogenic complex for eliciting protective immunity against group b streptococcus |
CA3066020A1 (en) | 2017-06-16 | 2018-12-20 | Glaxosmithkline Biologicals Sa | Method of treatment |
MX2022006054A (es) | 2019-11-22 | 2022-06-24 | Glaxosmithkline Biologicals Sa | Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos. |
EP4066854A1 (en) | 2021-03-29 | 2022-10-05 | MinervaX | Immunogenic fusion protein |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5302386A (en) * | 1986-04-16 | 1994-04-12 | Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines and methods of manufacture |
US4772584A (en) * | 1986-05-23 | 1988-09-20 | Cleary Paul P | Inhibitor of C5a-mediated chemotaxis |
EP0367890A1 (en) * | 1988-11-11 | 1990-05-16 | HighTech Receptor AB | Protein Arp, with immunoglobulin A binding activity, cloning and expression thereof |
IL95578A (en) * | 1989-09-15 | 1998-08-16 | Gen Hospital Corp | A vaccine made from polysaccharide and protein |
US5648241A (en) * | 1989-09-15 | 1997-07-15 | The General Hospital Corporation | Conjugate vaccine against group B streptococcus |
JPH06506114A (ja) * | 1991-03-29 | 1994-07-14 | ファウルマン, エルビン | 新規な遺伝子及びIgA結合蛋白質の製造方法 |
-
1994
- 1994-03-21 WO PCT/SE1994/000246 patent/WO1994021685A1/en active IP Right Grant
- 1994-03-21 PT PT94911348T patent/PT656014E/pt unknown
- 1994-03-21 KR KR1019950703989A patent/KR100331358B1/ko not_active IP Right Cessation
- 1994-03-21 EP EP94911348A patent/EP0656014B1/en not_active Expired - Lifetime
- 1994-03-21 HU HU9501993A patent/HU217582B/hu not_active IP Right Cessation
- 1994-03-21 DE DE69432658T patent/DE69432658T2/de not_active Expired - Lifetime
- 1994-03-21 CN CN94191519A patent/CN1046291C/zh not_active Expired - Fee Related
- 1994-03-21 SG SG1996004387A patent/SG47049A1/en unknown
- 1994-03-21 NZ NZ263275A patent/NZ263275A/en not_active IP Right Cessation
- 1994-03-21 ZA ZA941958A patent/ZA941958B/xx unknown
- 1994-03-21 DK DK94911348T patent/DK0656014T3/da active
- 1994-03-21 JP JP52094694A patent/JP3976334B2/ja not_active Expired - Fee Related
- 1994-03-21 SI SI9430453T patent/SI0656014T1/xx unknown
- 1994-03-21 ES ES94911348T patent/ES2194024T3/es not_active Expired - Lifetime
- 1994-03-21 CA CA002158658A patent/CA2158658A1/en not_active Abandoned
- 1994-03-21 AT AT94911348T patent/ATE240351T1/de not_active IP Right Cessation
-
1995
- 1995-06-07 US US08/487,675 patent/US5869064A/en not_active Expired - Fee Related
-
1998
- 1998-07-29 HK HK98109536A patent/HK1008825A1/xx not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002533083A (ja) * | 1998-12-22 | 2002-10-08 | マイクロサイエンス リミテッド | 遺伝子およびたんぱく質、およびそれらの用途 |
JP2002533065A (ja) * | 1998-12-22 | 2002-10-08 | マイクロサイエンス リミテッド | 外表面たんぱく質、それらの遺伝子、およびそれらの用途 |
Also Published As
Publication number | Publication date |
---|---|
DE69432658T2 (de) | 2004-04-08 |
NZ263275A (en) | 1997-07-27 |
KR960701096A (ko) | 1996-02-24 |
HU9501993D0 (en) | 1995-08-28 |
US5869064A (en) | 1999-02-09 |
AU681130B2 (en) | 1997-08-21 |
WO1994021685A1 (en) | 1994-09-29 |
DE69432658D1 (de) | 2003-06-18 |
CA2158658A1 (en) | 1994-09-29 |
HU217582B (hu) | 2000-02-28 |
EP0656014B1 (en) | 2003-05-14 |
EP0656014A1 (en) | 1995-06-07 |
AU6389194A (en) | 1994-10-11 |
KR100331358B1 (ko) | 2002-08-13 |
SI0656014T1 (en) | 2003-12-31 |
CN1119442A (zh) | 1996-03-27 |
ATE240351T1 (de) | 2003-05-15 |
JP3976334B2 (ja) | 2007-09-19 |
DK0656014T3 (da) | 2003-08-11 |
ES2194024T3 (es) | 2003-11-16 |
HUT72841A (en) | 1996-05-28 |
ZA941958B (en) | 1995-01-27 |
PT656014E (pt) | 2003-09-30 |
HK1008825A1 (en) | 1999-05-21 |
CN1046291C (zh) | 1999-11-10 |
SG47049A1 (en) | 1998-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stålhammar-Carlemalm et al. | Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. | |
KR100361562B1 (ko) | 프로테이나제k에대해내성을갖는네이쎄리아메닝기티디스의표면단백질 | |
Fischetti et al. | Size variation of the M protein in group A streptococci. | |
JP2974028B2 (ja) | アドヒシン抗原類 | |
Beachey et al. | Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. | |
JPH09500092A (ja) | B群れんさ球菌の多くの菌株に対する免疫を与える細胞表面タンパク質であるタンパク質Rib、そのタンパク質の精製方法、薬剤キットおよび医薬組成物 | |
FI107334B (fi) | Menetelmä rokotteen valmistamiseksi Lymen taudin estämiseksi | |
JP4785014B2 (ja) | 蛋白質 | |
US10261092B2 (en) | Cross-reactive determinants and methods for their identification | |
SK281324B6 (sk) | Polypeptid zo streptococcus suis, vakcína, spôsob výroby vakcíny a protilátky | |
JPH06508513A (ja) | マイコバクテリウムタンパク質およびその使用 | |
Ullmann et al. | Immunochemistry of the cell walls of Listeria monocytogenes | |
Cunningham et al. | Immunochemical properties of streptococcal M protein purified by isoelectric focusing | |
WO1995009181A1 (fr) | Peptide contenant une sequences d'acides amines de la proteine de franges de porphyromonas gingivalis, et utilisation dudit peptide | |
EP0726314A1 (en) | FIMBRILLIN PROTEIN OF $i(PORPHYROMONAS GINGIVALIS) | |
AU681130C (en) | Protein rib, a cell surface protein that confers immunity tomany strains of the group B streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition | |
Mett et al. | Fimbria-specific antibodies detach Escherichia coli from human cells | |
RU2102081C1 (ru) | Иммуногенная композиция против боррелиоза лайма, способ иммунизации млекопитающего против боррелиоза лайма, способ получения белка pc borrelia burgdorferi, диагностический агент для обнаружения b.burgdorferi и способ обнаружения антител к b.burgdorferi | |
WO2003059252A2 (en) | Use of a novel cell surface protease from group b streptococcus | |
JPH04501661A (ja) | マラリア抗原 | |
Al-Khafaji | The Inductive Effect of Purified Streptococcal M-protein on Immunity against Streptococcus pyogenes in Rabbit Model | |
St et al. | Protein Rib: A Novel Group B Streptococcal Cell Surface Protein that Confers Protective Immunity and Is Expressed by Most Strains Causing Invasive Infections | |
JP2004504056A (ja) | タンパク質 | |
WO2003013601A1 (en) | Toxin associated with sudden infant death syndrome, and uses thereof | |
EP0577224A1 (en) | Bacterial antigens, antibodies, vaccines and methods of manufacture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031225 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040528 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040624 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070508 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070619 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100629 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100629 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110629 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |